Click here to view in chapter format
Agenda
| 00:00:00 | Opening Remarks Dr. Subodh Verma |
| 00:00:52 | Targeting Inflammation in Atherosclerosis: Have we finally arrived? Dr. Paul M Ridker |
| 00:24:53 | Changing the PARADIGM in Heart Failure: What we have learned and where we are heading Dr. Scott D Solomon |
| 00:54:01 | Closing Remarks Dr. Subodh Verma |
Learning Objectives
- Explain the pathophysiology of inflammation in the genesis of atherothrombosis.
- Summarize the results of the CANTOS trial of inflammation targeting in secondary prevention.
- Discuss the changing landscape of heart failure treatments in HFpEF and HFrEF.
- Evaluate the ongoing clinical trials in the area of heart failure.
Faculty
Subodh Verma
MD, PhD, FRCSC, FAHA
Cardiac Surgeon, St. Michael’s Hospital
Professor of Surgery and Pharmacology & Toxicology, University of Toronto
Paul M Ridker
MD, MPH, FAHA, FACC
Eugene Braunwald Professor of Medicine, Harvard Medical School
Director, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital
Scott D Solomon
MD
Edward D Frohlich Distinguished Chair
Professor of Medicine, Harvard Medical School
Director, Noninvasive Cardiology, Brigham and Women’s Hospital
Video Information
- Credit:No Credit Available
- Post Date:July 16, 2018
- Expiry Date:N/A
